🇺🇸 SUTILAINS in United States

FDA authorised SUTILAINS on 12 June 1969 · 5 US adverse-event reports

Marketing authorisations

FDA — authorised 12 June 1969

  • Application: NDA012828
  • Marketing authorisation holder: ABBOTT
  • Local brand name: TRAVASE
  • Indication: OINTMENT — TOPICAL
  • Status: approved

Read official source →

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Blood Pressure Inadequately Controlled — 1 report (20%)
  2. Middle Insomnia — 1 report (20%)
  3. Nervousness — 1 report (20%)
  4. Nightmare — 1 report (20%)
  5. Palpitations — 1 report (20%)

Source database →

SUTILAINS in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Dermatology approved in United States

Frequently asked questions

Is SUTILAINS approved in United States?

Yes. FDA authorised it on 12 June 1969; FDA has authorised it.

Who is the marketing authorisation holder for SUTILAINS in United States?

ABBOTT holds the US marketing authorisation.